A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma

NCT01987492 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

230

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: Lebrikizumab
DRUG: Placebo

Sponsor

Hoffmann-La Roche